Atopic dermatitis Market

pharma-news-for-incyte-gilead-archeus

Jun 24, 2025

Incyte’s MONJUVI Combo Approved by FDA for Relapsed/Refractory Follicular Lymphoma; Gilead’s YEZTUGO Becomes First FDA-Approved HIV Prevention with 6-Month Protection; FDA Reviewing Incyte’s OPZELURA for Pediatric Atopic Dermatitis (Ages 2–11); Archeus Technologies Receives FDA Clearance for Prostate Cancer Therapy ART-101; Cycle Pharmaceuticals’ HARLIKU Gets First FDA Approval for Alkaptonuria

zoryve-for-atopic-dermatitis-treatment

Jul 19, 2024

ZORYVE for Atopic Dermatitis Treatment: Is the Breakthrough We’ve Been Waiting for?

atopic-dermatitis-treatment-pipeline

May 20, 2024

Atopic Dermatitis Treatment: Rich Portfolio of Therapeutic Options Shaping the Future

Pharma News for AskBio, Almirall, Bayer, Pfizer

Nov 21, 2023

Key Updates on Phase 1 Trial of AB-1005 Gene Therapy for Multiple System Atrophy-Parkinsonian Type; European Commission Approves EBGLYSS; Bayer Stopped OCEANIC-AF Study; Pfizer and Astellas’ XTANDI Approved by FDA; FDA Orphan Drug Designation to Epic Bio’s EPI-321; FDA Fast Track Designation to Chemomab’s CM-101 for PSC

dupixent-market

Mar 25, 2022

Can Dupixent Be A Gamechanger In The Atopic Dermatitis Treatment Landscape?

Atopic dermatitis market

Dec 31, 2019

Atopic dermatitis market and a Dupilumab dominance

Atopic dermatitis market

Dec 30, 2019

Atopic dermatitis market: Increasing prevalence and topical treatments

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper